We are live on ! Find out more
NRIX icon

Nurix Therapeutics
NRIX

128 hedge funds and large institutions have $352M invested in Nurix Therapeutics in 2023 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 41 increasing their positions, 51 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

30% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 10

18% more call options, than puts

Call options by funds: $104K | Put options by funds: $88K

2% more funds holding

Funds holding: 126 → 128 (+2)

1.02% more ownership

Funds ownership: 91.97% → 92.99% (+1%)

19% less capital invested

Capital invested by funds: $436M → $352M (-$83.2M)

20% less repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 51

Holders
128
Holders Change
+2
Holders Change %
+1.59%
% of All Funds
2.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
41
Reduced
51
Closed
10
Calls
$104K
Puts
$88K
Net Calls
+$16K
Net Calls Change
-$1.97M

Top Buyers

Rank Fund Capital Flow
1
SCM
Soleus Capital Management
Connecticut
+$7.43M
2
AIM
ARK Investment Management
Florida
+$3.03M
3
ACH
ArrowMark Colorado Holdings
Colorado
+$2.87M
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$1.83M
5
Charles Schwab
Charles Schwab
California
+$1.69M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$3.25M
2
HMC
Harvard Management Company
Massachusetts
-$3.14M
3
WA
Wasatch Advisors
Utah
-$2.79M
4
State Street
State Street
Massachusetts
-$1.38M
5
Nomura Holdings
Nomura Holdings
Japan
-$1.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
Millennium Management
26
Millennium Management
New York
$2.26M -$3.25M -356,254 -55%
WFA
27
WestHill Financial Advisors
California
$2.23M – – –
SCM
28
Suvretta Capital Management
New York
$2.21M – – –
Morgan Stanley
29
Morgan Stanley
New York
$1.99M +$405K +44,316 +21%
AAA
30
Affinity Asset Advisors
New York
$1.97M +$1.37M +150,000 +150%
Jacobs Levy Equity Management
31
Jacobs Levy Equity Management
New Jersey
$1.94M +$1.83M +200,184 +427%
UBS AM
32
UBS AM
Illinois
$1.89M -$55.7K -6,103 -2%
GCP
33
GSA Capital Partners
United Kingdom
$1.54M +$1.62M +177,852 +1,012%
Connor, Clark & Lunn Investment Management (CC&L)
34
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$1.45M +$488K +53,429 +41%
UBS Group
35
UBS Group
Switzerland
$1.35M +$834K +91,355 +113%
Bank of New York Mellon
36
Bank of New York Mellon
New York
$1.34M +$44K +4,816 +3%
KCM
37
Kennedy Capital Management
Missouri
$1.29M +$984K +107,719 +193%
Wellington Management Group
38
Wellington Management Group
Massachusetts
$1.14M +$38K +4,163 +3%
GC
39
Globeflex Capital
California
$1.1M -$24.4K -2,677 -2%
Marshall Wace
40
Marshall Wace
United Kingdom
$1M +$1.16M +127,509 New
Los Angeles Capital Management
41
Los Angeles Capital Management
California
$989K +$155K +16,989 +16%
Rafferty Asset Management
42
Rafferty Asset Management
New York
$777K -$143K -15,649 -14%
RJA
43
Raymond James & Associates
Florida
$770K +$50.6K +5,547 +6%
JRP
44
Jasper Ridge Partners
California
$752K – – –
TI
45
Trexquant Investment
Connecticut
$692K +$294K +32,212 +58%
VIG
46
Vienna Insurance Group
Poland
$668K – – –
Swiss National Bank
47
Swiss National Bank
Switzerland
$667K -$28.3K -3,100 -4%
Ensign Peak Advisors
48
Ensign Peak Advisors
Utah
$628K – – –
RhumbLine Advisers
49
RhumbLine Advisers
Massachusetts
$590K +$18.2K +1,993 +3%
Citadel Advisors
50
Citadel Advisors
Florida
$538K +$484K +53,002 +343%
1
2
3 4 5

NRIX Hedge Fund Activity: Q3 2023 in Review

128 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Nurix Therapeutics (NRIX) for Q3 2023, worth a combined $352M — down 19% from $436M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new NRIX positions and 10 closed out — a net gain of 3 holders — while 41 added to existing stakes and 51 trimmed.

The largest buyer was Soleus Capital Management, opening a new position worth an estimated $7.43M. The largest seller was Millennium Management, cutting an estimated $3.25M.

  • 128 institutional investors held Nurix Therapeutics (NRIX) as of Q3 2023, up from 126 in Q2 2023.
  • Funds reported $352M of Nurix Therapeutics stock for Q3 2023, down 19% quarter-over-quarter.
  • 13 funds opened new Nurix Therapeutics positions in Q3 2023 and 10 closed out, a net change of +3 holders.
  • The largest Nurix Therapeutics buyer in Q3 2023 was Soleus Capital Management, an estimated $7.43M added.
  • The largest Nurix Therapeutics seller in Q3 2023 was Millennium Management, an estimated $3.25M sold.

Based on aggregated 13F filings for Q3 2023.